Skip to main navigation Skip to search Skip to main content

Non-myeloablative stem cell transplant using 2-chlorodeoxyadenosine (2-CdA) in a patient with myelodysplastic syndrome (MDS)

Research output: Contribution to journalArticlepeer-review

Abstract

Non-myeloablative conditioning regimens for allogeneic stem cell transplant have become popular recently. With non-myeloablative conditioning, regimen-related toxicities (RRT) are mild and engraftment of allogeneic graft can be achieved consistently. We performed non-myeloablative allogeneic peripheral blood stem cell transplant using 2-chlorodeoxyadenosine (Cladribine; 2-CdA), busulfan, and anti-thymocyte globulin (ATG) for a patient with myelodysplastic syndrome (MDS). He also had hemochromatosis in the liver due to blood transfusions. His post-transplant clinical course was uncomplicated. Non-myeloablative conditioning regimen containing 2-CdA facilitates engraftment with minimal toxicity.

Original languageEnglish (US)
Pages (from-to)88-90
Number of pages3
JournalExperimental Oncology
Volume22
Issue number1-2
StatePublished - Mar 2000

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Non-myeloablative stem cell transplant using 2-chlorodeoxyadenosine (2-CdA) in a patient with myelodysplastic syndrome (MDS)'. Together they form a unique fingerprint.

Cite this